4 Accordingly, the manufacturer prescribing information for all currently available GLP-1 RAs includes a warning for increased risk of hypoglycemia when used in combination with an insulin secretagogue or insulin 5-11 and state that reducing the dose of the insulin secretagogue or insulin may be necessary to prevent hypoglycemia
Grace ND, West DM, Sargison ND
Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are being used increasingly for the management of type 2 diabetes mellitus (T2DM) or obesity because of their association with robust glucose lowering, weight loss, and cardiorenal benefits
HIPAA compliance is maintained throughout, and board-certified physicians write all prescriptions
Verify the formulary and benefit exclusion before assuming medical eligibility equals coverage
Trusted Partner for Private Label and Bulk Orders Recognized for reliability and innovation, Eskag Pharma is a trusted partner for private label brands and bulk orders, catering to both domestic and international markets with consistent quality and service